{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Risperidone%2C+Olanzapine&page=2",
    "query": {
      "intervention": "Risperidone, Olanzapine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 74,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Risperidone%2C+Olanzapine&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Risperidone%2C+Olanzapine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T22:31:41.681Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01556763",
      "title": "Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Central Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "EVP-6124 (0.3 mg/day)",
          "type": "DRUG"
        },
        {
          "name": "EVP-6124 (1.0 mg/day)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Antipsychotic therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FORUM Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 21,
      "start_date": "2008-04",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2012-06-21",
      "last_synced_at": "2026-10-06T22:31:41.681Z",
      "location_count": 1,
      "location_summary": "Wichita, Kansas",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01556763"
    },
    {
      "nct_id": "NCT03230864",
      "title": "Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Treatment-resistant Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Lu AF35700",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2017-07-20",
      "completion_date": "2019-02-05",
      "has_results": true,
      "last_update_posted_date": "2020-01-21",
      "last_synced_at": "2026-10-06T22:31:41.681Z",
      "location_count": 10,
      "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fall River",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03230864"
    },
    {
      "nct_id": "NCT00338949",
      "title": "Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Metabolic Syndrome X",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Switch",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veterans Medical Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 77,
      "start_date": "2006-06",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2020-10-30",
      "last_synced_at": "2026-10-06T22:31:41.681Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00338949"
    },
    {
      "nct_id": "NCT02282085",
      "title": "Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Aripiprazole Once-Monthly",
          "type": "DRUG"
        },
        {
          "name": "Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matt Byerly",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 200,
      "start_date": "2014-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-10-06T22:31:41.681Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02282085"
    },
    {
      "nct_id": "NCT01272765",
      "title": "Anti-psychotic Medication (Stable Dose) Weight Loss Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "IHBG-10",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Avera McKennan Hospital & University Health Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-03",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2012-06-01",
      "last_synced_at": "2026-10-06T22:31:41.681Z",
      "location_count": 1,
      "location_summary": "Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272765"
    },
    {
      "nct_id": "NCT00065273",
      "title": "Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mental Retardation",
        "Developmental Delay Disorder"
      ],
      "interventions": [
        {
          "name": "risperidone",
          "type": "DRUG"
        },
        {
          "name": "clozapine",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "6 Years to 60 Years"
      },
      "enrollment_count": 50,
      "start_date": "1998-07",
      "completion_date": "2001-06",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-06T22:31:41.681Z",
      "location_count": 1,
      "location_summary": "Lawrence, Kansas",
      "locations": [
        {
          "city": "Lawrence",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00065273"
    },
    {
      "nct_id": "NCT01231074",
      "title": "Reducing Antipsychotic-Induced Weight Gain in Children With Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity",
        "Weight Gain",
        "Psychotropic Induced Weight Gain"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 96,
      "start_date": "2010-02",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2019-01-02",
      "last_synced_at": "2026-10-06T22:31:41.681Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01231074"
    },
    {
      "nct_id": "NCT00190749",
      "title": "Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 130,
      "start_date": "2003-10",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2010-05-04",
      "last_synced_at": "2026-10-06T22:31:41.681Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00190749"
    },
    {
      "nct_id": "NCT00222495",
      "title": "A Comparative Study of New Medications for Psychosis in Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Psychotic Disorders",
        "Schizophrenia",
        "Schizophreniform Disorders",
        "Schizoaffective Disorders"
      ],
      "interventions": [
        {
          "name": "quetiapine",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 30,
      "start_date": "2002-08",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2006-09-11",
      "last_synced_at": "2026-10-06T22:31:41.681Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00222495"
    },
    {
      "nct_id": "NCT00048802",
      "title": "Treatment and Outcome of Early Onset Bipolar Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Lithium",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Divalproex",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        },
        {
          "name": "Ziprasidone",
          "type": "DRUG"
        },
        {
          "name": "Aripriprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 40,
      "start_date": "2002-08",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2014-01-22",
      "last_synced_at": "2026-10-06T22:31:41.681Z",
      "location_count": 1,
      "location_summary": "Glen Oaks, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048802"
    }
  ]
}